SCHEMBL13218219

SCHEMBL13218219

Brc1csc(C#Cc2ccc3c(c2)OCO3)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 1/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
HSD17B10 Q99714 3/20 0.39
NPC1 O15118 6/20 0.38
RAB9A P51151 5/20 0.38
GRM5 P41594 1/20 0.37
MEN1 O00255 6/20 0.37
KMT2A Q03164 6/20 0.37
LMNA P02545 2/20 0.37
ACACB O00763 1/20 0.37
PTGS2 P35354 1/20 0.36
MAPT P10636 6/20 0.36
NFKB1 P19838 2/20 0.36
NFKB2 Q00653 2/20 0.36
RELA Q04206 2/20 0.36
GSTO1 P78417 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
CFTR P13569 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13217613 0.83 GRM5 (0.54) TGFBR1SMN1; SMN2HSD17B10NPC1RAB9A
SCHEMBL13218220 0.80 OGA (0.46) TGFBR1SMN1; SMN2HSD17B10NPC1RAB9A
SCHEMBL13218217 0.74 GRM5 (0.51) NPC1RAB9AGRM5MEN1KMT2A
SCHEMBL13218227 0.73 NPC1 (0.42) TGFBR1SMN1; SMN2HSD17B10NPC1RAB9A
SCHEMBL13218221 0.72 GRM5 (0.57) SMN1; SMN2HSD17B10GRM5
SCHEMBL6313419 0.72 GRM5 (0.66) SMN1; SMN2NPC1RAB9AGRM5MEN1
SCHEMBL13238172 0.71 TGFBR1 (0.55) TGFBR1SMN1; SMN2HSD17B10NPC1RAB9A
SCHEMBL13218229 0.68 SMN1; SMN2 (0.38) SMN1; SMN2HSD17B10NPC1RAB9AGRM5
SCHEMBL13218187 0.68 KMT2A (0.49) TGFBR1SMN1; SMN2HSD17B10NPC1RAB9A
SCHEMBL10300112 0.68 ACACB (0.52) SMN1; SMN2GRM5LMNAACACBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100216787-A1 THIAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2010-08-26 US disclosed
US-7678810-B2 Thiazole derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2010-03-16 US disclosed
US-20070154428-A1 Thiazole derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216787-A1 THIAZOLE DERIVATIVE TGFBR1, TGFBR2, SMAD3 TGFBR1 1/4885SMN1; SMN2 4805/4885HSD17B10 1212/4885
US-20070154428-A1 Thiazole derivative TGFBR1, TGFBR2, SMAD3 TGFBR1 1/4885SMN1; SMN2 4805/4885HSD17B10 1212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.